NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $532.89 million. The enterprise value is $549.37 million.
| Market Cap | 532.89M |
| Enterprise Value | 549.37M |
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 34.09 million shares outstanding. The number of shares has increased by 11.22% in one year.
| Current Share Class | 34.09M |
| Shares Outstanding | 34.09M |
| Shares Change (YoY) | +11.22% |
| Shares Change (QoQ) | +0.99% |
| Owned by Insiders (%) | 3.92% |
| Owned by Institutions (%) | 67.24% |
| Float | 23.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.35 |
| Forward PS | 5.07 |
| PB Ratio | 36.67 |
| P/TBV Ratio | 36.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.38, with a Debt / Equity ratio of 4.87.
| Current Ratio | 5.38 |
| Quick Ratio | 4.25 |
| Debt / Equity | 4.87 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.46 |
Financial Efficiency
Return on equity (ROE) is -111.38% and return on invested capital (ROIC) is -11.49%.
| Return on Equity (ROE) | -111.38% |
| Return on Assets (ROA) | -10.02% |
| Return on Invested Capital (ROIC) | -11.49% |
| Return on Capital Employed (ROCE) | -20.26% |
| Weighted Average Cost of Capital (WACC) | 13.79% |
| Revenue Per Employee | $452,409 |
| Profits Per Employee | -$98,023 |
| Employee Count | 220 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 1.43 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.99% in the last 52 weeks. The beta is 1.88, so NeuroPace's price volatility has been higher than the market average.
| Beta (5Y) | 1.88 |
| 52-Week Price Change | +44.99% |
| 50-Day Moving Average | 16.25 |
| 200-Day Moving Average | 14.28 |
| Relative Strength Index (RSI) | 46.64 |
| Average Volume (20 Days) | 143,635 |
Short Selling Information
The latest short interest is 582,943, so 1.71% of the outstanding shares have been sold short.
| Short Interest | 582,943 |
| Short Previous Month | 613,817 |
| Short % of Shares Out | 1.71% |
| Short % of Float | 2.50% |
| Short Ratio (days to cover) | 2.75 |
Income Statement
In the last 12 months, NeuroPace had revenue of $99.53 million and -$21.57 million in losses. Loss per share was -$0.65.
| Revenue | 99.53M |
| Gross Profit | 77.93M |
| Operating Income | -16.76M |
| Pretax Income | -21.57M |
| Net Income | -21.57M |
| EBITDA | -16.51M |
| EBIT | -16.76M |
| Loss Per Share | -$0.65 |
Balance Sheet
The company has $53.98 million in cash and $70.46 million in debt, with a net cash position of -$16.48 million or -$0.48 per share.
| Cash & Cash Equivalents | 53.98M |
| Total Debt | 70.46M |
| Net Cash | -16.48M |
| Net Cash Per Share | -$0.48 |
| Equity (Book Value) | 14.45M |
| Book Value Per Share | 0.43 |
| Working Capital | 70.81M |
Cash Flow
In the last 12 months, operating cash flow was -$9.42 million and capital expenditures -$412,000, giving a free cash flow of -$9.84 million.
| Operating Cash Flow | -9.42M |
| Capital Expenditures | -412,000 |
| Depreciation & Amortization | 249,000 |
| Net Borrowing | -2.07M |
| Free Cash Flow | -9.84M |
| FCF Per Share | -$0.29 |
Margins
Gross margin is 78.29%, with operating and profit margins of -16.84% and -21.67%.
| Gross Margin | 78.29% |
| Operating Margin | -16.84% |
| Pretax Margin | -21.67% |
| Profit Margin | -21.67% |
| EBITDA Margin | -16.59% |
| EBIT Margin | -16.84% |
| FCF Margin | n/a |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.22% |
| Shareholder Yield | -11.22% |
| Earnings Yield | -4.05% |
| FCF Yield | -1.85% |
Analyst Forecast
The average price target for NeuroPace is $20.00, which is 27.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.00 |
| Price Target Difference | 27.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 15.32% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -3.66 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.66 |
| Piotroski F-Score | 4 |